(Reuters) – The U.S. government will allocate nearly 85 percent less of Johnson & Johnson’s COVID-19 vaccine to the state next week, data from the Centers for Disease Control and Prevention (CDC) showed.
Only 785,500 doses will be allocated J&J, compared to 4.95 million doses this week. The U.S. Department of Health and Human Services (HHS) and J&J did not immediately respond to a request made outside of normal business hours to comment on the drop in numbers.
A New York Times report last week said workers at an emergency BioSolutions plant in Baltimore that produced both AstraZeneca Plc and J&J in mixed doses, the combination of the two vaccines destroyed 15 million doses of J&J.
The Baltimore facility, however, is not yet banned from the U.S. Food and Drug Administration, and federal health officials told Reuters last week that factory vaccines were not used for vaccination.
J&J has reiterated that it expects to deliver 100 million doses to the government by the end of May.
According to the CDC, California is the primary recipient of J&J vaccine, followed by Texas and Florida. Vaccine allocations for California are down about 88%, with the state set to receive a maximum of 67,600 doses next week.
California health officials told Reuters the numbers will drop further this week starting April 18, with just 22,400 doses of the J&J vaccine allocated to the state.
On Tuesday, U.S. President Joe Biden promoted all American adults’ COVID-19 eligibility targets to April 19.
Reporting by Shubham Kalia and Aakriti Bhalla in Bengaluru; Edited by Simon Cameron-Moore